An across-the-board clinical trial registry analysis spells out the effect of measures to slow the spread of the new coronavirus.
Covid-19 could mean Medtronic loses out to Abbott, its rival in the mitral valve space.
The failure of a crucial pivotal study consigns Blueprint’s lead drug, Ayvakit, to a tiny niche.
As investors continue to jump on small sparks of hope in the pandemic pipeline Sanofi and Regeneron inject a dose of reality.
Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.
A Vantage analysis suggests which small biotechs might seriously have to rethink R&D spending plans in the wake of Covid-19.
A Vantage analysis identifies 315 pivotal trials that, like Lexicon’s Scored and Soloist studies, risk never being completed.
Novo Nordisk is in danger of being left behind in haemophilia, and new safety fears around its lead R&D project make this more likely. But could a setback prompt deal…